



ASX ANNOUNCEMENT

6 November 2015

Restricted Securities to be released from Escrow

In accordance with ASX Listing Rule 3.10A, the Board of Cynata Therapeutics Ltd (ASX: CYP) hereby advises that the following restricted securities are due for release from escrow on 29 November 2015:

Security Description	Release Date	Number
Unlisted Options expiring 27/9/2018 (CYPAL) Ex \$0.40	29 November 2015	5,000,000
Unlisted Options expiring 09/9/2016 (CYPAL) Ex \$0.40	29 November 2015	500,000

Media contacts: Dr Ross Macdonald, CEO: Tel: 0412 119343; email ross.macdonald@cynata.com
Dr Stewart Washer, Executive Chairman: Tel: 0418 288212; email stewart.washer@cynata.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform delivers a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.